文献速递骨肌神经技术与安全PETCTMR

脊索瘤的18F-FDG PET/CT与MRI影像特征

Chordoma: 18F-FDG PET/CT and MRI imaging features.
PubMed 文献 · Skeletal Radiol · 2021-02-01

回顾性分析23例经活检证实的脊索瘤患者的治疗前18F-FDG PET/CT及MRI影像特征,其中22例有可比MRI。结果显示脊索瘤呈中度不均匀FDG摄取,平均SUVmax 5.8±3.7;MRI上多表现为T2高信号、T1等信号伴小灶性T1高信号。PET/CT与MRI参数间无统计学显著关联,且SUVmax、MTV、TLG、最大径及体积与复发或转移无显著关系。

要点

  • 脊索瘤在18F-FDG PET/CT上呈中度、不均匀FDG摄取,平均SUVmax 5.8±3.7。
  • MRI上脊索瘤多表现为T2高信号(22/22)、T1等信号(18/22),常含小灶性T1高信号(17/22)。
  • PET/CT代谢参数及MRI大小参数与复发或转移无统计学显著关联。

关键影像表现/征象

  • 18F-FDG PET/CT上所有脊索瘤均表现为不均匀FDG活性,平均SUVmax 5.8±3.7,平均代谢肿瘤体积(MTV)160.2±263.8 cm³,平均总病灶糖酵解(TLG)542.6±1210 g。
  • MRI上脊索瘤主要呈T2高信号(22/22)和T1等信号(18/22),17/22例含有小灶性T1高信号,14/20例呈不均匀强化。
  • 病变部位包括骶尾部13例、活动脊柱9例和斜坡1例。

诊断标准与关键数值

  • 18F-FDG PET/CT参数:平均SUVmax 5.8±3.7,平均MTV 160.2±263.8 cm³,平均TLG 542.6±1210 g。
  • MRI信号特征:T2高信号22/22,T1等信号18/22,小灶性T1高信号17/22,不均匀强化14/20。

临床应用与阅片要点

  • 阅片时注意脊索瘤在18F-FDG PET/CT上呈中度、不均匀FDG摄取,SUVmax平均值5.8±3.7可作为参考。
  • MRI上关注T2高信号、T1等信号及小灶性T1高信号等常见表现,有助于鉴别。
  • 原文指出18F-FDG PET/CT可能是用于分期、评估治疗反应及评估复发或转移的有用方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Examine the 18F-FDG PET/CT and MRI imaging characteristics of chordoma.

MATERIALS AND METHODS: Biopsy-proven chordoma with a pre-therapy 18F-FDG PET/CT from 2001 through 2019 in patients > 18 years old were retrospectively reviewed. Multiple PET/CT and MRI imaging parameters were assessed.

RESULTS: A total of 23 chordoma patients were included (16 M, 7 F; average age of 60.1 ± 13.0 years) with comparative MRI available in 22 cases. This included 13 sacrococcygeal, 9 mobile spine, and one clival lesions. On 18F-FDG PET/CT, chordomas demonstrated an average SUVmax of 5.8 ± 3.7, average metabolic tumor volume (MTV) of 160.2 ± 263.8 cm3, and average total lesion glycolysis (TLG) of 542.6 ± 1210 g. All demonstrated heterogeneous FDG activity. On MRI, chordomas were predominantly T2 hyperintense (22/22) and T1 isointense (18/22), contained small foci of T1 hyperintensity (17/22), and demonstrated heterogeneous enhancement (14/20). There were no statistically significant associations found between 18F-FDG PET/CT and MRI imaging features. There was no relationship of SUVmax (p = 0.53), MTV (p = 0.47), TLG (p = 0.48), maximal dimension (p = 0.92), or volume (p = 0.45) to the development of recurrent or metastatic disease which occurred in 6/22 patients over a mean follow-up duration of 4.1 ± 2.0 years.

CONCLUSION: On 18F-FDG PET/CT imaging, chordomas demonstrate moderate, heterogeneous FDG uptake. Predominant T2 hyperintensity and small foci of internal increased T1 signal are common on MRI. The inherent FDG avidity of chordomas suggests that 18F-FDG PET/CT may be a useful modality for staging, evaluating treatment response, and assessing for recurrent or metastatic disease.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. Olson JT, Wenger DE, Rose PS, et al. Chordoma: 18F-FDG PET/CT and MRI imaging features. Skeletal Radiol. 2021. PMID: 33521875. doi:10.1007/s00256-021-03723-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。